Ajanta Pharma shares jumped 2.67% to ₹3,552.10 on the NSE after the company disclosed its September‑quarter results, lifting investor confidence.
The pharmaceutical firm reported net profit of ₹388 crore, a 49% jump from ₹260.2 crore in the same period last year; revenue climbed 32.5% to ₹1,794.2 crore, up from ₹1,354 crore.
Operating metrics improved sharply—EBITDA rose to ₹547.6 crore, pushing the margin to 30.5% from 24.2% year‑on‑year.
No forward guidance was released, but analysts expect the company to maintain its growth trajectory into Q3 FY27, driven by its expanding product pipeline and robust domestic sales.
The stock’s lift reflects a broader uptick in the pharmaceutical sector, where peers have also posted higher margins this quarter, underscoring the industry’s resilience.